Muscarinic cholinergic mediation of opiate and non-opiate environmentally induced analgesias

Age differences in nociception and pain behaviours in the rat

Much remains to be learned about the effects of ageing on pain. Studies of life-span changes in nociception and pain behaviours in the rat are equivocal making it difficult to draw firm conclusions. This paper reviews the available data and finds that age differences in nociception may be dependent on the pain test employed. Specifically, reflexive responses to nociceptive stimuli do not change with age while there may be no change or a linear decrease with age on more highly organized tests of nociception. Interestingly, age differences in pain behaviours on models of tissue injury and inflammation may not be linear. It is shown that important changes that begin at mid-life in neuroanatomy, neurochemistry and endogenous pain inhibition may be associated with alterations in pain sensitivity. Several testable hypotheses which might encourage future research in this domain are developed throughout this paper.

Physostigmine's impact on brief shock-induced hypoalgesia parallels its effect on memory

Past research indicates that the anticholinergic drug scopolamine disrupts memory and environmentally induced hypoalgesia in rats. The present study examined the impact of the centrally active cholinesterase inhibitor physostigmine, which enhances memory and central cholinergic activity, on brief shock-induced hypoalgesia on the tail-flick test using Sprague-Dawley rats. It is reported that physostigmine (0.1 mg/kg) potentiates the magnitude of this hypoalgesia. Contrary to past research, our results showed that omission of baseline testing did not eliminate hypoalgesia or its potentiation by physostigmine. Similar to its effects on memory, physostigmine (0.04, 0.1, and 0.25 mg/kg) has a nonmonotonic impact on brief shock-induced hypoalgesia; low doses potentiated hypoalgesia (0.1 mg/kg), whereas a high dose (0.25 mg/kg) disrupted it. These results provide further evidence that the cholinergic system indirectly affects pain reactivity by modulating the memory of the aversive event.

Descending antinociceptive mechanisms in the brainstem: their role in the animal's defensive system

The identification of specialized mechanisms in the mammalian brainstem that function to inhibit the rostral transmission of nociceptive (pain-related) information in the spinal cord led to an explosion of research into the neuroanatomical and neurochemical substrates of these antinociceptive systems. As outlined in the present paper, most attention was directed at those mechanisms in the periaqueductal grey (PAG) and rostral ventromedial medulla (RVM). However, comparatively little attention has been paid to the functional role of these mechanisms in animal behaviour. The purpose of the present paper is to review research into the behavioural significance of those antinociceptive mechanisms in the PAG and RVM. It is concluded that these mechanisms function as part of the animal's fear or defensive system, serving to make a threatened animal insensitive to noxious stimulation and thereby allowing that animal to engage in defensive responses instead of recuperative activities. Further, it is argued that the organization of these antinociceptive circuits reflects the animal's increasing capacity for early detection of danger. Specifically, nociception itself is held to signify the presence of immediate threat, and consequently, nociceptive input directly activates antinociceptive circuits at either the spinal level (during intense noxious stimulation) or RVM (following exposure to moderate noxious stimuli). In contrast, events that are themselves innocuous but which signal threat (either learned or innate danger signals) activate fear and defensive systems in the amygdala and PAG which engage the descending antinociceptive projections in the RVM.

Stress-induced behavioral responses and multiple opioid systems in the brain

Various stressor produce a wide range of behavioral responses such as analgesia, catalepsy and motor suppression, which are sensitive to opioid receptor antagonists. These behavioral responses in stress are accompanied by changes in the contents of opioid peptides, the mRNAs encoding their precursors and opioid receptor binding in the brain. In the present article, experimental data concerning stress-induced analgesia and motor suppression is reviewed and discussed in relation to a possible involvement of different opioid systems in the various observed behavioral responses in stress. Pharmacological studies with subtype-selective antagonists have demonstrated that not only mu- but also delta- and/or kappa-opioid receptors are involved in opioid-mediated stress-induced analgesia. There are two types of stress-induced analgesia referred to as opioid-mediated and non-opioid mediated forms. It has been proposed that the intensity and temporal pattern of stressor may be a critical factor determining the nature of stress-induced analgesia. Accumulated evidence demonstrate that these two forms of pain inhibitory systems interact each other according to a collateral inhibition model. Recent studies show that parallel activation of multiple opioid receptors mediates non-opioid froms of stress-induced analgesia. Dynorphins, by acting at kappa-opioid receptors, may play a pivotal role in the expression of stress-induced motor suppression, whereas enkephalins may act to attenuate this response.

Attenuation of cholinergic analgesia by nifedipine

Nociception was tested in mice receiving oxotremorine or physostigmine either after the dihydropyridine calcium channel blocker nifedipine or the non-calcium antagonist vasodilator hydralazine. Nifedipine did not change the reaction time to thermal stimulation (tail-flick test), but attenuated the prolonging action on tail-flick latencies exerted by the two cholinomimetic agents. Hydralazine had no effect alone nor modified the action of cholinomimetics. The results suggest that attenuation of cholinergic analgesia by nifedipine might be related to not yet defined neuronal changes produced by calcium channel blockade, but changes in the pharmacokinetics of oxotremorine and physostigmine cannot be ruled out.

The role of peripheral sudomotor blockade in the treatment of patients with sympathetically maintained pain

The aim of the present study was to investigate the role of the peripheral cholinergic system in patients with sympathetically maintained pain (SMP). Thirty-three patients with SMP were given Bier's block with 0.6 mg of atropine in 10 ml of saline or 10 ml of saline in a randomised double-blind manner. Pain intensity, pain relief and mood were assessed before and after each block using the visual analogue scale (VAS). In addition pain intensity was assessed at the same time using a categorical scale (CS). There was at least 1 week between each injection, and during this week the patients reported their pain intensity daily, using the CS. Three patients failed to complete both wings of the study and thus the results of the remaining 30 patients were analysed using the Mann-Whitney U test and the Wilcoxon signed-rank test. No significant difference was found between atropine and saline on any parameter.

Serotonergic influence on cholinergic-induced analgesia: differences in two inbred strains of mice

C57BL/6 (C57) and DBA/2 (DBA) inbred mice showed different analgesic responses to cholinergic stimulation. The simultaneous administration of muscarinic and serotonergic agonists, oxotremorine and 5-methoxy-NN-dimethyltryptamine (5-MeODMT), lowered the antinociceptive effect of the cholinergic drug in DBA mice, while no effects were detectable in the C57 strain. These results suggest a strain-dependent behavioural effect of the interaction of cholinergic and serotonergic neuronal systems.

Respiratory failure without pulmonary edema following injection of a glutamate agonist into the ventral medullary raphe of the rat

Injection of ibotenic acid (IA), a glutamate agonist, into the ventral medullary raphe (VMR; especially the nucleus raphe magnus) of the rat produced respiratory failure and death following a predictable course of events. The response to the IA injection was characterized initially by increased respiratory frequency and was followed by pulmonary arterial hypertension, systemic arterial hypoxemia, acidosis, and hypothermia. Within 90 min apnea occurred as a terminal event in all animals. Gravimetric, bronchoalveolar lavage protein, and histological analyses revealed no evidence of pulmonary edema. Intracerebral (VMR) pretreatment with PPP, a sigma receptor agonist, or scopolamine, a muscarinic cholinergic antagonist, prevented pulmonary failure and death even though postmortem histological analysis showed VMR cell loss and gliosis consequent to the cytotoxic IA injection. Based on the results of the study, it is suggested that the VMR has a role in regulation of pulmonary blood flow. Preliminary pharmacological studies suggested that a disruption of glutamatergic and cholinergic mechanisms mediates the lethal pulmonary phenomenon.

The effect of cobrotoxin on cholinergic neurons in the mouse

By using multiple time-point constant-rate infusions of deuterium-labeled phosphorylcholine, appropriate kinetic parameters were obtained for use in the calculation of the turnover rate of acetylcholine (TRACh) in selected mouse brain regions. After obtaining these data, the relationship between the analgesic agent cobrotoxin (CT) and the activity of central cholinergic neurons was investigated by determination of TRACh in selected mouse brain regions 3 hours following intracerebroventricular (i.c.v.) injection of CT. There were no obvious changes in the concentrations of ACh and choline (Ch) in the cortex, hippocampus, hypothalamus, midbrain, striatum, or thalamus of the mouse after injection of an analgesic dose of CT (2 micrograms, i.c.v.). TRACh in the thalamus and the striatum were significantly increased, as compared to controls. On the other hand, i.c.v. injection of CT was found to significantly reduce TRACh in the hippocampus and midbrain. These results suggest that the activity of hippocampal and midbrain cholinergic neurons is suppressed by CT, whereas the activity of striatal and thalamic cholinergic neurons is increased by CT at a time when a maximum analgesic response to CT is expressed.

Roles of gender and gonadectomy in pilocarpine and clonidine analgesia in rats

Central and systemic morphine analgesia as well as both opioid and nonopioid forms of swim analgesia display gender differences with male rats showing greater magnitudes of analgesia than female rats. Since nonopioid swim analgesia is dependent upon muscarinic cholinergic and alpha 2-noradrenergic mechanisms, the present study evaluated in rats whether gender, adult gonadectomy or estrous phase altered analgesia induced by either the muscarinic cholinergic receptor agonist, pilocarpine or the alpha 2-noradrenergic receptor agonist, clonidine. Pilocarpine (1-10 mg/kg) analgesia was significantly greater in male rats. Female rats displayed 7-fold and 3-fold rightward shifts in peak analgesia on the tail-flick and jump tests respectively. Clonidine (100-500 micrograms/kg) analgesia was significantly greater on both nociceptive tests in males, but only produced a 2-fold rightward shift in peak analgesia in females on the jump test. Whereas castration failed to shift either dose-response curve, ovariectomy mitigated the gender differences in pilocarpine and clonidine analgesia. Both pilocarpine and clonidine analgesia were not altered by estrous phase changes. These data indicate that gender differences in analgesia are not specific to opioid systems.

Reduction of oxotremorine-induced analgesia after chronic but not acute restraint stress

The analgesic response (tail-flick latency) induced by the muscarinic cholinergic agonist oxotremorine was investigated in DBA/2 mice exposed to acute (a single 2 h session) and chronic (2 h once daily for 10 days) restraint stress. While a single exposure to stress did not influence the antinociceptive effects of the cholinergic agonist, chronic stress induced a clear-cut reduction of the oxotremorine-induced analgesia. The results show an involvement of cholinergic mechanisms in the adaptive modulation of nociception after chronic stressful events.

Age-related cholinergic drug effects on analgesia in two inbred strains of mice

The two inbred strains of mice C57BL/6 and DBA/2 are characterized by a different behavioral reactivity to cholinergic agents during development. The present experiment revealed that the strain-dependent differences in cholinergic-mediated analgesia during development disappeared during adult life. In fact, oxotremorine administration (0.0025 and 0.005 mg/kg) exerted the same analgesic effect in both strains at 6 months of age, in contrast with the finding of the lack of any effect of the drug in C57 mice at two months of age in comparison with DBA.

Developmental differences of antinociceptive effects of oxotremorine in two inbred strains of mice

During development the C57BL/6 and DBA/2 mouse strains present morphological variations in cholinergic forebrain structures correlated with different behavioral reactivities to cholinergic agents. The present research assessed that these strain-dependent differences are also present in cholinergic-mediated analgesia. The administration of oxotremorine (0.0025, 0.005 and 0.01 mg/kg) to 30- and 60-day-old C57 and DBA mice resulted in dose- age- and strain-dependent analgesia. In particular oxotremorine is more effective in DBA/2 than in C57BL/6 mice and the latter strain showed a significant decrease of analgesic response in adulthood.

Physostigmine-induced analgesia in young, middle-aged, and senescent rats

To investigate the effect of aging on cholinergically medicated analgesia, rats from three age groups (3-month, 17-month, and 25-month) were injected with physostigmine (0.0156, 0.0625, or 0.25 mg/kg) or saline. Following the injection, tail-flick latencies were measured at 5-minute intervals for 30 minutes and at 45, 60, 75 and 90 minutes. The analysis of the tail-flick latencies revealed that physostigmine produced a dose-dependent analgesia in all age groups. However, the 17- and 25-month-old age groups were more sensitive to the highest dose of physostigmine. The age-related differences in the analgesia produced by physostigmine is in agreement with other research which has demonstrated that pharmacological stimulation of the cholinergic system produces an equivalent or increased responsivity in aged animals.

Developmental aspects of nociception

Research has documented the existence of multiple, endogenous systems that modulate nociception. Based on the effects of opioid antagonists and endocrine lesions, endogenous analgesia systems have been organized into four classes: neural-opioid, neural-nonopioid; hormonal-opioid; hormonal-nonopioid. Developmental research on the ontogeny of endogenous analgesic function has revealed differential rates of maturation. Front-paw shock, a stimulus that activates a neural-opioid analgesic response, has been shown to be functionally mature by 28 days of age in the rat. Similarly, hind-paw shock, a stimulus that elicits a neural-nonopioid analgesic response, reaches maturity after two months of age. However, the hormonal-opioid analgesic system activated by cold-water immersion reaches adult levels by 10 days of age. Food deprivation produces a hormonal-opioid analgesic response in adult rats, and food deprivation/isolation of rat pups has been found to elicit an analgesic response in 6-day-old rats. From these data it seems that the rate of development of the different endogenous analgesic systems is related to the activation of neural or hormonal components. Whether the differential rates of development and the neural-hormonal distinction are related to the ecological validity of the activating stimulus remains to be determined.

Effects of anticholinergic treatment on transient behavioral suppression and physiological responses following concussive brain injury to the rat

Increasing doses (0.1, 1.0, 10.0 mg/kg) of scopolamine were systemically (i.p.) administered to rats subjected to moderate fluid percussion brain injury. Scopolamine treatment (1.0 mg/kg, i.p.) 15 min prior to trauma significantly reduced mortality and the duration of transient behavioral suppression assessed by a variety of measures. No differences were observed between saline- and scopolamine-treated animals in either the incidence or duration of transient apnea associated with injury. Preinjury treatment with methylscopolamine (1.04 mg/kg) or mecamylamine (1.0 mg/kg) had no effect on transient behavioral suppression. Except for increased heart rate, preinjury treatment with scopolamine (1.0 mg/kg) did not significantly alter systemic physiological responses to injury. Rats treated with scopolamine (1.0 mg/kg, i.p.) 30 s after injury tended to have shorter durations of reflex and response suppression. These experiments suggest that antimuscarinics can attenuate components of transient behavioral suppression associated with concussive brain injury. These findings are consistent with previous experimental and clinical observations and lend further support to the hypothesis that activation of a muscarinic system within the CNS mediates components of reversible traumatic unconsciousness following cerebral concussion.

The dorsal raphe nucleus: a re-evaluation of its proposed role in opiate analgesia systems

Previous studies have concluded that (a) electrical stimulation in the periaqueductal gray/dorsal raphe nucleus (PAG/DRN) region specifically produces either non-opiate or opiate forms of antinociception dependent upon the dorsoventral level of stimulation and (b) the 'opiate' form of stimulation-produced analgesia (SPA) arising from the ventral PAG/DRN region shows cross-tolerance with opiate forms of footshock analgesia, implying common neural substrates. This latter conclusion in turn implies that SPA elicited from the ventral PAG/DRN region would be expected to be antagonized by scopolamine, since this muscarinic cholinergic antagonist blocks opiate footshock analgesia. The present study demonstrates instead that neither 10 mg/kg naloxone nor 10 mg/kg scopolamine had any effect on SPA elicited from sites histologically verified to lie within the presumptive 'opiate' ventral PAG/DRN region. These data bring into question both the site specificity of opiate SPA and the common mediation of ventral PAG/DRN SPA and opiate forms of footshock analgesia.

Parametric and pharmacological studies of midbrain suppression of the hind limb flexion withdrawal reflex in the rat

These experiments quantitatively analyzed effects of electrical midbrain stimulation on a nociceptive hind limb flexion reflex in rats anesthetized with sodium pentobarbital. We recorded the force of isometric hind limb flexion withdrawal, and related flexor electromyographic (EMG) activity, elicited by noxious heat (42-54 degrees C, 10 sec) applied to the ventral hind paw. Several hind limb flexors including biceps femoris were active during the reflex. Quantified reflex responses to identical noxious heat stimuli delivered every 2 min were constant in magnitude and were reduced or abolished during stimulation (100 msec trains at 100 Hz, 3/sec, 15-325 microA) in the midbrain periaqueductal gray (PAG) or lateral reticular formation (LRF). LRF was significantly more effective than PAG stimulation in suppressing reflex responses. The magnitude of the reflex responses increased with graded increases in the temperature of the noxious heat stimulus. The slope of the temperature-response relationship was significantly reduced during PAG stimulation, whereas it was shifted toward higher temperatures with significantly increased threshold during LRF stimulation. To investigate possible transmitters involved, we tested if PAG- or LRF-evoked reflex suppression was affected following systemic administration of the opiate antagonist naloxone, the serotonin antagonist methysergide, the noradrenergic antagonist phentolamine, or the cholinergic antagonist scopolamine. Naloxone had little effect, while methysergide and phentolamine reduced PAG- and LRF-evoked reflex suppression in about one-half of the cases. Scopolamine largely reduced PAG- and LRF-evoked reflex suppression (in 8/9 and 4/6 rats, respectively). These results indicate that the flexion reflex is under parametrically but not pharmacologically distinct inhibitory midbrain controls.

Ontogeny of an endogenous, nonopioid and hormonally mediated analgesic system

Rats of different ages (10-day, 28-day, and 3-month-old) were exposed to cold-water stress in order to activate an endogenous analgesic system. The effects of naltrexone (7 mg/kg) and dexamethasone (.4 mg/kg) were also studied to examine the role of the opioid and hormonal systems in cold-water-induced analgesia. Following cold-water exposure, nociception was measured with the tail-flick procedure for 2 hr. Results revealed that cold water produced a significant level of analgesia in the 10-day, 28-day, and 3-month-old age groups with no differences between age groups. In addition, in each age group naltrexone did not block the analgesia while dexamethasone attenuated the analgesia produced by cold water. The effects of naltrexone and dexamethasone confirm that cold-water immersion activates a nonopioid, hormonally mediated analgesic system in each age group. Thus, this experiment found that the endogenous, nonopioid, and hormonally mediated analgesic system activated by cold water is functional early in the development of the rat. The early development of this hormonally mediated analgesic system is in contrast to the slower development of endogenous analgesia systems that are mediated by the central nervous system.

Developmental differences in the analgesia produced by the central cholinergic system

In order to study the ontogenesis of cholinergically mediated analgesia in the central nervous system (CNS), 10-day-, 28-day-, and 3-month-old rats were injected with .025, .05, and .10 mg/kg of oxotremorine, a muscarinic receptor agonist. To restrict the effect of oxotremorine to the CNS, methylscopolamine, a peripheral muscarinic antagonist, was injected simultaneously (.19 mg/kg, a dose equimolar to .10 mg/kg of oxotremorine). Following drug injections the tail-flick procedure was used to assess analgesia. Results revealed that oxotremorine was completely ineffective in producing analgesia in the 10-day- and 28-day-old age groups. By 3 months of age oxotremorine produced a dose-dependent analgesia. Since most neurochemical markers of cholinergic receptor function are at mature or near mature levels by 28 days of age, neurochemical indexes of receptor function overestimate the analgesic function of the central cholinergic system.

Short-term and delayed behavioral effects of pre- and post-weaning morphine in mice

Ninety mouse pups of the CD-1 outbred strain were used to assess activity (Varimex Activity Meter, Columbus Instr., OH) and analgesia (hot plate) after morphine hydrochloride given IP either on days 14-16 (preweanlings) or on days 21-23 (postweanlings). In preweanlings morphine depressed activity already at the lowest dose tested (0.5 mg/kg), and higher doses (1, 5, and 10 mg/kg) did not produce a significantly larger effect. Activity of postweanlings was not depressed until a very high dose (20 mg/kg). By contrast, morphine produced clear analgesic effects at all doses in both preweanlings (day 14) and postweanlings (day 21). Around day 70, activity and hot-plate tests in the no-drug state showed no differences due to prior treatment, except for the fact that hot-plate latencies of mice previously injected with saline as preweanlings were higher than those of all other groups. Twenty-four hr later the tests were repeated after morphine injection (10 mg/kg), and showed a significantly greater depression of activity in mice previously exposed as preweanlings. On the other hand, all groups previously exposed to morphine at either the pre- or the post-weanling stage showed tolerance to the analgesic effect of the drug. These developmental profiles confirm that opioid systems contribute to the modulation of activity by mechanisms which are at least in part separate from those mediating analgesia.

Nociceptive responses to altered GABAergic activity at the spinal cord

GABA agonists and antagonists were injected intrathecally at the spinal cord, to determine their effect on nociceptive thresholds. Tactile stimulation, applied against the flank by a medium diameter von Frey fiber (5.5 g force), elicited distress vocalizations after, but not before injection of the GABA antagonists, bicuculline MI or picrotoxin (0.25 and 1 microgram dosages). Vocalization threshold to tail shock was significantly reduced by bicuculline MI or picrotoxin. Tail flick withdrawal latency from radiant heat was not altered by GABA antagonists. The GABA agonist, muscimol, significantly elevated vocalization threshold to tail shock at a 5 micrograms dose. At a lower dose level (1 microgram), muscimol significantly reduced vocalization threshold to tail shock. Tail flick latency was significantly prolonged by the 5 micrograms dose of muscimol; however, flaccid paralysis of the hind limbs was also evident. Nociceptive thresholds were not altered by GABA or saline injection. These findings indicate that GABAergic activity contributes to the tonic modulation of nociception at the spinal cord.

The analgesia produced by food deprivation in 4-month old, 14-month old, and 24-month old rats

The analgesia produced by 24 hr of food deprivation was examined in 4-mo, 14-mo, and 24-mo old rats. To assess opioid and hormonal involvement in food deprivation induced analgesia, different groups of rats from each age group were injected with naltrexone (7 mg/kg), dexamethasone (0.4 mg/kg), or equivolume saline. Results revealed that food deprivation produced an equivalent analgesic response in each saline-treated age group. Also, naltrexone and dexamethasone were equally potent in blocking food deprivation induced analgesia in each age group. These results demonstrated that food deprivation activates an endogenous opioid-mediated analgesic system that involves hormonal factors and that this system does not change in function with increasing age.

Opioid, cholinergic and alpha-adrenergic influences on the modulation of nociception from the lateral reticular nucleus of the rat

The lateral reticular nucleus (LRN) has been identified as an area in the caudal medulla involved in the centrifugal modulation of spinal nociceptive transmission and withdrawal reflexes. The data presented in this report further support a role for the LRN in the modulation of nociceptive responses. It was confirmed in the present study that focal electrical stimulation in the LRN inhibits the nociceptive tail-flick (TF) reflex at low intensities of stimulation in lightly pentobarbital-anesthetized rats. Aversive effects, however, were typically produced at similar and higher intensities of stimulation in the LRN in the same rats in the awake state. It was also determined that an inhibitory modulation of nociceptive responses organized both spinally and supraspinally could be activated independently by muscarinic cholinergic or opioid mechanisms in the LRN. Microinjection of morphine into the LRN in conscious rats produced an antinociception in both TF and hot plate (HP) tests which could be attenuated significantly by naloxone, but not atropine, previously microinjected into the same site in the LRN. Carbachol microinjected into the LRN also produced an antinociception which was attenuated significantly by atropine but not naloxone previously microinjected into the same site in the LRN. In contrast, the microinjection of clonidine or norepinephrine into the LRN either did not affect or shortened significantly response latencies in the TF and HP tests. These results further establish that the LRN contributes to the modulation of nociception. Opioid and cholinergic influences in the LRN appear to independently activate inhibition of responding to nociceptive stimuli organized either spinally or supraspinally, although descending inhibition was most clearly activated. An action at alpha 2 adrenoceptors in the LRN, conversely, produces an hyperalgesia as reflected by shortened latencies to respond in TF and HP tests.

Arcuate nucleus lesions reduce opioid stress-induced analgesia (SIA) and enhance non-opioid SIA in rats

When rats were tested more than two weeks following surgery, lesions of the medial basal hypothalamus centered on the arcuate nucleus enhanced a form of foot-shock stress-induced analgesia (SIA) that was not blocked by injections of the opiate receptor blocker, naltrexone (6 mg/kg;). These arcuate nucleus lesions reduced the SIA produced by the same stressor when similar rats were tested 3-4 days following surgery. Finally, when similar rats were tested more than 2 weeks following surgery these lesions reduced a different form of SIA that was blocked by naltrexone. There were no effects of the lesions or naltrexone on baseline pain reactivity in any of the experiments. We suggest that arcuate nucleus lesions disrupt a system important for the elaboration of opiate-mediated SIA (Expt. 4), perhaps by damaging the brain's beta-endorphin system. In response to damage to this opioid analgesic system, we hypothesize that the damaged brain initiates time-dependent compensatory changes in an undamaged non-opioid analgesic system, resulting in enhanced non-opiate-mediated SIA.

Effects of muscarinic receptor antagonism upon two forms of stress-induced analgesia

The present study assessed in rats the effects of muscarinic receptor antagonism upon analgesia induced by cold-water swims (CWS: 2 degrees C for 3.5 min) and 2-deoxy-D-glucose (2DG: 600 mg/kg). First, CWS analgesia was significantly reduced 30 min after the swim by scopolamine (0.01 and 0.1 mg/kg) and methylscopolamine (10 mg/kg) pretreatment, and was eliminated 60 min after the swim by scopolamine (0.01-10 mg/kg) and methylscopolamine (1,10 mg/kg) pretreatment. In contrast, scopolamine potentiated CWS hypothermia. Second, while scopolamine (1 mg/kg) and methylscopolamine (1,10 mg/kg) pretreatment prolonged 2DG analgesia, both antagonists dose-dependently reduced 2DG hyperphagia. Third, the changes in analgesic and hypothermic stress responses were not due to baseline shifts in jump thresholds or body temperatures. However the dose-dependent reductions by scopolamine and methylscopolamine in baseline food intake and 2DG hyperphagia were significantly correlated. Fourth, the dose-dependent reduction by scopolamine and methylscopolamine of pilocarpine analgesia differed in pattern from the other analgesic effects, suggesting heterogeneity in muscarinic receptor modulation of different analgesic responses.

Range of environmental stimuli producing nociceptive suppression: implications for neural mechanisms

Initial studies of environmentally induced analgesia in the rat established several important characteristics of this phenomenon. We demonstrated that stressful environmental stimuli were not sufficient to produce nociceptive suppression. However, emphasis by many researchers on stress-related analgesia has limited studies of the range of environmental contexts producing nociceptive suppression and handicapped efforts to describe neural mechanisms mediating EIA. Another feature of EIA was the observation that the nervous system might contain multiple opiate and non-opiate systems capable of modulating nociceptive responses. Although previous research had recognized the possibility of endogenous opiate analgesic systems, little attention had been given to non-opiate analgesic mechanisms. Since it seems unlikely that multiple systems would serve purely redundant roles, it seemed reasonable to speculate that at least some of these systems may mediate other modulatory functions in addition to regulating sensory information on noxious stimuli. The observation that some environmental conditions could increase nociceptive responses certainly indicated that environmentally induced nociceptive modulation was not restricted to analgesia. These and other observations lead us to suspect that neural mechanisms mediating at least some forms of EIA could be related to mechanisms mediating more general modulating processes associated with selective attention, orienting, or arousal. Subsequent studies in the primate established that changes in vigilance demands, stimulus relevance, and stimulus predictability could modulate responses of medullary dorsal horn nociceptors coding sensory-discriminative information on noxious thermal stimuli. However, these studies provided no information on the neural mechanisms mediating this modulation. Later studies in cats described an endogenous, non-narcotic analgesic system representing a subcomponent of a larger cholinergic system principally involved in regulating animals' responsiveness to external stimuli. Research also indicated that this cholinergic analgesic system could function physiologically to modulate nociceptive responsiveness in the presence of certain environmental stimuli but not others. Considered together, data from these studies indicate that, while stress is not sufficient to produce analgesia, a variety of environmental conditions can modulate nociceptive input. A number of different neural systems could contribute EIA associated with various stimuli. It is possible that the regulation of nociceptive input is not the exclusive, or even principal, consequence of normal activity within certain of these systems.

Two opioid forms of stress analgesia: studies of tolerance and cross-tolerance

We have previously reported that stress analgesia sensitive to and insensitive to opiate antagonists can be differentially produced in rats by varying the severity or temporal pattern of inescapable footshock. In these studies, we give further evidence for the opioid and non-opioid bases of these paradigms of stress analgesia. We find that naloxone-sensitive analgesia demonstrates tolerance with repeated stress and cross-tolerance with morphine, whereas naloxone-insensitive analgesia demonstrates neither of these characteristics. Moreover, different forms of opioid, but not non-opioid, stress analgesia manifest cross-tolerance with each other. These data are discussed in terms of the similarities and differences between two forms of opioid stress analgesia.

Environmentally induced analgesia: ontogeny of a nonopioid system

Previous research has demonstrated that exposure to 90 sec of hind paw shock activates an endogenous pain control system that involves cholinergic sites. The purpose of the present investigation was to examine the development of function of this nonopioid analgesic system. Research on the ontogeny of the cholinergic system suggests that this receptor system exhibits an extended period of postnatal development, with various neurochemical indexes reaching maturity between 30 to 50 days of age. Results revealed that exposure to hind paw shock produced very low levels of analgesia in 10- and 28-day-old rats. The analgesic response was more evident in 2-month-old rats, but the degree of hind paw shock-induced analgesia was not at its maximum until 3 months of age. Systemic injection of naltrexone had no effect on the degree of analgesia induced by hind paw shock, while a systemic injection of scopolamine significantly attenuated the analgesia displayed by the 28-day-old and 2- and 3-month-old rats. Thus, the neurochemical indexes of cholinergic development over-estimated the degree of functional maturity of the endogenous analgesia system activated by hind paw shock.

Differential effects of scopolamine on 3 forms of stress analgesia

We have previously reported that non-opioid stress analgesia and two forms of opioid stress analgesia can be differentially produced in rats by varying the severity or temporal pattern of inescapable footshock. In this study, we investigated the role of muscarinic cholinergic mechanisms in mediating these 3 forms of stress analgesia. Whereas the muscarinic anticholinergic drug, scopolamine, had no effect on either non-opioid stress analgesia or opioid stress analgesia from 1 min of continuous 2.5-mA footshock, it significantly attenuated opioid analgesia from 20 min of intermittent footshock at this same intensity. The data are discussed in reference to other similarities and differences between these two forms of opioid stress analgesia.

Drug and environmentally induced manipulations of the opiate and serotonergic systems alter nociception in neonatal rat pups

The influence of drug- and environmentally induced alterations in serotonergic and opiate activity on pain sensitivity was assessed in 6-day-old Sprague-Dawley-derived rat pups using tail flick-testing procedures. The opiate agonist morphine was observed to induce tail flick analgesia that was blocked by concurrent administration of the opiate antagonist naloxone. Similarly, the serotonergic agonist quipazine induced analgesia that was blocked by pretreatment with the serotonergic antagonist metergoline. Naloxone alone did not alter tail flick responsivity in non-isolated, nondeprived neonates, suggesting that the opiate system may not exert a significant tonic inhibition of pain sensitivity in neonates. In contrast, the serotonergic system may exert some tonic analgesic influence at this age, given that metergoline was observed to induce slight hyperalgesia in nondeprived, non-isolated neonates. Twenty four hours of food and maternal deprivation, shown previously to increase brain serotonin and 5-hydroxyindole acetic acid and their ratio in neonates (L. P. Spear & F. M. Scalzo, 1984, Developmental Brain Research, in press) was observed to induce tail flick analgesia, an effect blocked by metergoline. Isolation from siblings and the dam and nest for 30 min also induced tail flick analgesia; this analgesia was blocked by treatment with naloxone prior to testing. Together, these experiments support the suggestion that the serotonergic and opiate systems may regulate pain sensitivity even in neonatal rat pups, with agonist- or environmentally precipitated increases in serotonergic or opiate activity inducing significant analgesia during the early postnatal period.

Sensitization or tolerance to morphine effects after repeated stresses

Rats were subjected to prolonged footshock, intensive acoustic stress, cold water swim and restraint over a period of 10 days. The analgesic and thermoregulatory properties of morphine (2, 4 and 8 mg/kg, sc.) were tested on the 11th day. Analgesia assessment was performed by means of hot-plate (HP) and tail-flick (TF) tests, and body temperature (Tb) changes was measured. Prolonged footshock and acoustic stress increased the sensitivity to morphine, while repeated restraint lessened morphine's effect. Cold water swim caused ambiguous consequences, facilitated the effect of a small dose of morphine, but reduced that of a large dose. It was concluded that the sensory components of the stressful exposure determine the effects of repeated stress on morphine sensitivity. Whereas painful interventions led to sensitization, and non-painful procedures result in tolerance to morphine's effects. The finding that analgesic and thermoregulatory effects of morphine were simultaneously enhanced supports the contention that the mechanism of sensitization to opiates involves a site where pathways mediating opiate analgesia and thermoregulatory effects converge.

Bilateral lesions of the dorsolateral funiculus of the cat spinal cord: effects on basal nociceptive reflexes and nociceptive suppression produced by cholinergic activation of the pontine parabrachial region

In cats, bilateral microinjections of the cholinergic agonist, carbachol (0.6 micrograms in 0.2 microliter), into an area surrounding the lateral half of the brachium conjunctivum (BC) produces a non-narcotic suppression of nociceptive responses, as assessed by flexion reflexes (tail-flick and calibrated pinch tests). Bilateral lesions of the dorsolateral funiculi (DLF) of the thoracic spina cord (T2) significantly reduced the magnitude of this nociceptive suppression. Nociceptive suppression following carbachol microinjections into sites along the dorsal aspect of BC was reduced by DLF lesions to a greater degree than nociceptive suppression following injections into sites within or ventral to BC. Relatively superficial DLF lesions produced reductions in nociceptive suppression which were equivalent to reductions induced by deeper lesions. DLF lesions, either superficial or deep, produced equivalent, reliable decreases in tail-flick test assessments of baseline nociceptive thresholds. The magnitude of decreases in baseline nociceptive thresholds produced by DLF lesions was not correlated with the magnitude of reduction of carbachol-induced suppression of nociceptive responses, indicating that DLF lesions suppress anti-nociception independent of baseline alterations. These data suggest that non-narcotic analgesia produced by cholinergic activation of cells along the dorsal aspect of BC may be predominantly mediated by fibers descending within the DLF. However, results of the retrograde horseradish peroxidase (HRP) tracing studies reported in the present investigation indicate that this pain suppression is probably mediated by polysynaptic pathways since this region dorsal to BC projects neither through DLF nor extra-DLF pathways. Retrograde HRP data show that areas ventral to and including BC projects to the cord via both DLF and extra-DLF pathways. Since DLF lesions were less effective in reducing analgesia attained from ventral compared to dorsal sites, spinal pathways other than DLF may mediate reflex suppression following carbachol microinjection into these more ventral sites. Possible cholinergic contributions to endogenous, non-opiate forms of analgesia are discussed.

Evidence for involvement of cholinoceptive cells of the parabrachial region in environmentally induced nociceptive suppression in the cat

We have previously observed that activation of muscarinic receptors within the pontine parabrachial region (PBR) of cats produces potent analgesia. This study demonstrated that bilateral microinjections of the muscarinic antagonist atropine (each 4.0 micrograms in 1.0 microliter) into PBR attenuated nociceptive suppression elicited by exposure of cats to novel environmental changes without affecting general responsiveness to environmental stimulation. This observation suggests that muscarinic cholinoceptive cells in PBR function physiologically to modulate nociceptive responsiveness in response to certain environmental stimuli.

Non-opiate analgesia induced by carbachol microinjection into the pontine parabrachial region of the cat

These studies investigated the effect of microinjection of the cholinergic agonist carbamylcholine (carbachol) into various sites of the dorsolateral pontine tegmentum of the cat. Carbachol microinjection into an area surrounding the lateral half of the brachium conjunctivum (parabrachial region, PBR) produced profound suppression of nociceptive responses. In the dorsal part of PBR, carbachol microinjection produced no generalized sensory, emotional or motor deficits, indicating that nociceptive transmission was primarily affected. Carbachol microinjection into the ventral part of PBR resulted in slight suppression of motor responses in addition to profound nociceptive suppression. Carbachol-produced analgesia (CPA) observed within PBR blocked supraspinally as well as spinally integrated responses normally elicited by either phasic or tonic noxious stimuli. Atropine sulfate, but not mecamylamine hydrochloride, significantly antagonized CPA, indicating that muscarinic receptors mediate this phenomenon. The opiate antagonist naloxone, systemically administered either prior to or after carbachol microinjection, did not reliably attenuate CPA. Microinjection of morphine into the sites from which CPA had previously been obtained did not produce significant effects on nociceptive responses. Thus, opiate mechanisms appear not to be necessary either for the activation of this system or for the production of the resultant analgesia. These findings indicate that the neural population examined in the present study is anatomically and pharmacologically distinct from previously identified opiate-mediated pain inhibitory systems. Results are discussed in light of other recent evidence indicating the existence of endogenous non-opiate pain inhibitory systems.